Xyntha Alternatives Compared
| Xyntha (antihemophilic factor) | Advate (antihemophilic factor) | Hemlibra (emicizumab) |
|
|---|
| Xyntha (antihemophilic factor) | Advate (antihemophilic factor) | Hemlibra (emicizumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Hemophilia A. Xyntha may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Hemophilia A. Advate may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Hemophilia A with Inhibitors, Hemophilia A. Hemlibra may also be used for purposes not listed in this medication guide. |
Related suggestions |
|||||||||||||||||||||||
| More about Xyntha (antihemophilic factor) | More about Advate (antihemophilic factor) | More about Hemlibra (emicizumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Be the first to share your experience with this drug. |
Advate has an average rating of 9.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Hemlibra has an average rating of 10.0 out of 10 from a total of 2 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Xyntha side effects |
View all Advate side effects |
View all Hemlibra side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Xyntha prices |
View all Advate prices |
View all Hemlibra prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other antihemophilic factor brands include: Advate, Adynovate, Afstyla, Altuviiio, Beriate P, Bioclate, Biostate, Eloctate, Esperoct, Factane, Fanhdi, Genarc, Helixate FS, Hemofil-M, Hyate:C, Jivi, Koate, Koate-DVI, Kogenate FS, Kovaltry, Monoclate-P, NovoEight, Nuwiq, Obizur, Recombinate View more | Other antihemophilic factor brands include: Adynovate, Afstyla, Altuviiio, Beriate P, Bioclate, Biostate, Eloctate, Esperoct, Factane, Fanhdi, Genarc, Helixate FS, Hemofil-M, Hyate:C, Jivi, Koate, Koate-DVI, Kogenate FS, Kovaltry, Monoclate-P, NovoEight, Nuwiq, Obizur, Recombinate, Xyntha View more |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
24 hours |
24 hours |
667.2 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 10 drugs are known to interact with Xyntha:
|
A total of 10 drugs are known to interact with Advate:
|
A total of 8 drugs are known to interact with Hemlibra:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
N/A |
November 16, 2017 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Lysteda
Lysteda (tranexamic acid) is used to treat heavy menstrual bleeding. Includes Lysteda side effects ...
Hemlibra
Hemlibra is a monoclonal antibody that functions in place of a natural blood-clotting factor that ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
DDAVP
DDAVP is used for diabetes insipidus, hemophilia a, primary nocturnal enuresis, von Willebrand Disease
Qfitlia
Qfitlia is used for hemophilia a, hemophilia a with inhibitors, hemophilia b, hemophilia b with ...
Altuviiio
Altuviiio is a once-weekly recombinant fact VIII replacement therapy used by hemophilia A patients ...
Cyklokapron
Cyklokapron is used for bleeding disorder, factor ix deficiency, hemophilia a
Hympavzi
Hympavzi (marstacimab-hncq) may be used to prevent or reduce the frequency of bleeding episodes ...
Emicizumab
Emicizumab is used for hemophilia a, hemophilia a with inhibitors
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.